Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
Pembrolizumab actief bij klassiek en endemisch kaposisarcoom
apr 2022 | Bot en wekedelentumoren, Immuuntherapie